TSHA
HEALTHCARETaysha Gene Therapies Inc
AI Insight
What's Moving TSHA Today?
No stock-specific AI insight has been generated for TSHA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.25$7.30
$6.86
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-0.38
Dividend Yield—
Dividend / Share—
ROE-97.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding287.4M
TSHA News
21 articles- TSHA Maintained by B of A Securities -- Price Target Raised to $10.00GuruFocus·Jun 23, 2026
- Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)Advfn·Jun 22, 2026
- Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett SyndromeYahoo Finance·Jun 22, 2026
- Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year RecoveryYahoo Finance·Jun 13, 2026
- Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?Yahoo Finance·Jun 11, 2026
- Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026Yahoo Finance·May 14, 2026
- Canaccord Keeps Buy Rating on Taysha (TSHA) After Q1 HighlightsYahoo Finance·May 11, 2026
- Assessing Taysha Gene Therapies (TSHA) Valuation After Strong Momentum And Recent VolatilityYahoo Finance·May 9, 2026
- Taysha Gene Therapies, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Taysha Gene Therapies Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 6, 2026
- Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6GlobeNewswire Inc.·Apr 29, 2026
- Has Taysha Gene Therapies (TSHA) Run Too Far After A 259% One Year Surge?Yahoo Finance·Apr 28, 2026
- Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingYahoo Finance·Apr 27, 2026
- Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago LevelsYahoo Finance·Apr 22, 2026
- This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to BuyYahoo Finance·Apr 14, 2026
- Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome TreatmentYahoo Finance·Apr 6, 2026
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- Structure Therapeutics Slides 28% This Year as $6 Million Stake EmergesMotley Fool·Mar 22, 2026
- How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment StoryYahoo Finance·Mar 21, 2026
- Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...Yahoo Finance·Mar 19, 2026
All 21 articles loaded
Price Data
Open$6.47
Previous Close$6.86
Day High$7.06
Day Low$6.46
52 Week High$7.30
52 Week Low$2.25
52-Week Range
$2.25$7.30
$6.86
Fundamentals
Market Cap$1.9B
P/E Ratio—
EPS$-0.38
Dividend Yield—
Dividend / Share—
ROE-97.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding287.4M
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company is headquartered in Dallas, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—